The micro-cap market is a sorting mechanism. Companies enter with bold promises and exit via forced mergers, bankruptcy filings, or frantic eleventh-hour covenant waivers. This week’s filings are a masterclass in the end-stages of the corporate lifecycle. We have two distressed acquisitions, a Chapter 11 filing featuring a classic private equity roll-up, a repeat offender in the reverse-split arena, and a used-car lender begging its creditors for a long weekend to avoid insolvency.
America's Car-Mart (CRMT): The 96-Hour Reprieve
You know things are bleak when your lender gives you exactly 96 hours to figure out your life. On September 4, America's Car-Mart disclosed a four-day waiver extension from Silver Point Finance regarding existing covenant defaults, pushing the termination date to September 11. Car-Mart is drowning in negative working capital and has explicitly warned that a restructuring could wipe out common equity.
But the market is a strange place. On Monday, CRMT stock surged nearly 30% to $3.12 simply because they didn't file for bankruptcy over the weekend. A special committee is currently huddled with FTI Consulting and Houlihan Lokey trying to secure a last-minute capital raise. When four days of oxygen triggers a massive rally, you aren't investing; you're just gambling on the timing of the autopsy.
BioXcel Therapeutics (BTAI): The Stalking Horse
BioXcel missed an August deadline to refinance $107 million in debt owed to Oaktree Capital, and the result is a textbook distressed asset strip. The company filed for voluntary Chapter 11 bankruptcy and will be delisted from Nasdaq on September 8. They secured high-interest DIP financing from Oaktree and the Qatar Investment Authority, which rolls prepetition debt into super-priority status.
BioXcel is entering Chapter 11 not to reorganize, but to run a Section 363 asset sale. Teva Pharmaceuticals has already stepped in as the stalking-horse bidder with a $57.5 million cash offer for BioXcel's only approved drug, IGALMI. Given the massive debt load and the super-priority status of Oaktree's DIP facility, the math here is brutal. Trade creditors and common shareholders are staring at a near-total wipeout.
LivePerson (LPSN): Swallowed Whole
LivePerson is officially off the board. The company completed its merger with SoundHound AI, filed its Form 15, and terminated its SEC reporting obligations. The board resigned en masse, and all outstanding warrants and options were canceled for zero consideration.
This wasn't just a simple equity buyout; it was a debt restructuring masquerading as a merger. SoundHound retired LivePerson's secured convertible notes by handing the noteholders massive blocks of SOUN stock and a bit of cash. Retail LPSN holders get SOUN stock, while SoundHound inherits 25 Fortune 100 customers and a pristine, debt-free balance sheet. It is a clean, ruthless piece of corporate engineering.
Senti Biosciences (SNTI): The Reverse Split Habit
Senti Biosciences has an impressive ability to burn capital. The company received two deficiency notices from Nasdaq: one for trading under a dollar, and another for holding negative stockholders' equity of $3.4 million. To keep the lights on, Senti just authorized another $2 million convertible note tranche to NSG BioInnovation Fund.
To fix the Nasdaq problem, they are prepping a reverse stock split. If this sounds familiar, it's because SNTI executed a 1-for-10 reverse split in July 2024 for the exact same reason. You can shrink the share count as many times as you want, but eventually, you have to generate actual equity value. They have until February 23, 2027 to find some.
NCS Multistage (NCSM): A Quiet Exit
NCS Multistage is voluntarily pulling its listing after closing its sale to Weatherford International on September 1. The deal values NCS shares at roughly 0.463 Weatherford shares apiece, with about 20% of the consideration paid in cash.
It is a clean exit for a micro-cap oilfield services provider, offering $15 million in immediate cost synergies for Weatherford. NCS is now a wholly owned subsidiary, its reporting obligations are dead, and the executives have surrendered their shares as part of the exit package. No drama, just a standard corporate consolidation.
What to Watch
Watch the pink sheets this week for the BioXcel fallout, and keep a very close eye on Thursday’s deadline for America's Car-Mart. If Silver Point doesn't extend the waiver past September 11, expect a Chapter 11 filing before the markets open next Monday.